Free tool
FAERS Monitor: Infed
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017441 or its brand name (Infed, Iron Dextran). Reports on generic versions are filed under their own applications.
Reports
1,486
Serious
956
64% of reports
Hospitalization
354
Death reported
124
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea264
- infusion related reaction167
- nausea126
- flushing115
- anaphylactic reaction112
- back pain111
- chest pain102
- dizziness88
- chest discomfort85
- pruritus81
- off label use80
- hypotension72
- vomiting66
- headache61
- diarrhoea59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 49 |
| 2006 | 48 |
| 2007 | 46 |
| 2008 | 43 |
| 2009 | 39 |
| 2010 | 36 |
| 2011 | 39 |
| 2012 | 60 |
| 2013 | 26 |
| 2014 | 17 |
| 2015 | 34 |
| 2016 | 45 |
| 2017 | 47 |
| 2018 | 68 |
| 2019 | 60 |
| 2020 | 61 |
| 2021 | 99 |
| 2022 | 91 |
| 2023 | 92 |
| 2024 | 143 |
| 2025 | 172 |
| 2026 | 126 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,673 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 167 | 35.7 | 31.0 | 5,609 |
| anaphylactic reactionSignal | 112 | 28.7 | 24.1 | 2,974 |
| flushingSignal | 115 | 16.0 | 13.4 | 1,611 |
| chest discomfortSignal | 85 | 11.8 | 9.6 | 829 |
| chest painSignal | 102 | 7.8 | 6.5 | 603 |
| back painSignal | 111 | 6.8 | 5.7 | 545 |
| dyspnoeaSignal | 264 | 6.6 | 5.9 | 1,284 |
| hypotensionSignal | 72 | 5.1 | 4.1 | 234 |
| pruritusSignal | 81 | 3.0 | 2.4 | 107 |
| dizzinessSignal | 88 | 2.5 | 2.0 | 79 |
| nauseaSignal | 126 | 2.3 | 1.9 | 90 |
| vomiting | 66 | 2.0 | 1.6 | 32 |
| headache | 61 | 1.4 | 1.1 | 6 |
| diarrhoea | 59 | 1.3 | 1.0 | 4 |
| off label use | 80 | 1.3 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.